19659001 Avalon Pharma concerns prospectus to list 6M shares on TASI Logo design of Middle East Pharmaceutical Industries Co. (Avalon Pharma) 19659003 Middle East Pharmaceutical Industries Co. ( Avalon Pharma 19459008 revealed the prospectus for providing 6 million shares, representing 30% of its share capital, on the Saudi Exchange ( 19459009 Tadawul. 19659004 The Capital Market Authority (CMA) authorized, in December 2023, Avalon Pharma’s application for the share offering. The membership duration for taking part celebrations and the book-building procedure will run for 5 days from Jan. 14-18. 19659006 The retail offering will run for 3 days from Jan. 30 to Feb. 1. Based on the prospectus, getting involved celebrations will at first be designated 6 million shares, representing 100% of the overall shares available. 19659008 In case retail customers register for all shares assigned to them, the bookrunner will deserve to lower the variety of shares assigned to the taking part celebrations to 5.4 million shares as a minimum, representing 90% of the offering shares. 19659009 1.8 million shares will be allocated to the public funds classification, representing 30% of the overall. This figure might be slashed to 1.62 million shares if there suffices need from retail customers. Retail customers will be set aside an optimum of 600,000 shares of the overall offering, or 10% of the provided shares. Avalon Pharma establishes, produces, markets and disperses a variety of pharmaceuticals and generic medications in Saudi Arabia and abroad. According to its business register, the business’s activity is represented in disinfectants and sterilizers for medical gadgets and items. This remains in addition to the production of disinfectants and sterilizers for non-medical usage, along with cosmetics and pharmaceutical preparations for human usage. Business Profile 19659014 Business Avalon Pharma Market 19659017 Tadawul (TASI) 19659018 Core Activities Pharmaceuticals Capital 19659021 SAR 200 mln 19659022 Variety of Shares SAR 20 mln 19659024 IPO Summary 19659025 Concern Percentage 30% of capital Variety Of Offer Shares 19659028 6 mln Certified Subscribers 19659030 Taking part celebrations – Retail financiers 19659031 Minimum Limit for Retail Investors 19659032 10 shares 19659033 Minimum Limit for Institutional Investors 19659034 10,000 shares Optimum Limit for Retail Investors 19659036 600,000 shares 19659037 Optimum Limit for Institutional Investors 990,000 19659039 shares Institutional Offering & & Book-Building Period Jan.14-18, 2024 Retail Offering 19659043 Jan. 30-Feb. 1, 2024 19659044 Last Allocation Feb. 8, 2024 Refund (if any) Feb. 14, 2024 Extra Information 19659049 Financial Advisor & & Bookrunner Aldukheil Financial Group Lead Manager & & Underwriter Alinma Investment Getting Banks Alinma Bank – Saudi National Bank (SNB) 19659055 Significant Shareholders Investors Pre-IPO Post-IPO Variety of shares (mln shares) 19659061 Ownership Stake (%) Variety of shares (mln shares) 19659065 Ownership Stake 19659066 (%) 19659067 Tabbaa National Holding Co. 19659068 12.05 19659069 60.25 19659070 % 8.44 19659072 42.18 19659073 % 19659074 Talal Yousuf Zahid 4.20 21.00 % 19659078 2.94 19659079 14.70 19659080 % Ali Shaher Ahmad Al-Tabbaa 1.32 19659083 6.60 % 0.92 4.62 % 19659088 Faisal Shaher Ahmad Al-Tabbaa 19659089 1.28 19659090 6.40 19659091 % 19659092 0.90 4.48 % 19659095 Durrat Al-Wadaa Investment Co. 19659096 0.50 19659097 2.50 19659098 % 19659099 0.35 19659100 1.75 % 19659102 Yousuf Talal Yousuf Zahid 19659103 0.40 19659104 2.00 % 19659106 0.28 1.40 19659108 % 19659109 Durrat Al-Faisal Investment Co. 19659110 0.25 1.25 % 0.18 19659114 0.88 19659115 % 19659116 Public — 19659118– 6.00 19659120 30.00 19659121 % 19659122 Overall 20.00 19659124– 19659125 20.00 19659126 100 19659127 % Find out more
Avalon Pharma plans 6M share sale on TASI
